Ventricular flutter

Articolo redatto e revisionato del Dott. Luca Moretti

Ventricular flutter is an electrocardiographic term used to describe extremely rapid, relatively regular ventricular activity with confluent complexes and an almost sinusoidal pattern. Distinguishing the QRS complex, ST segment, and T wave becomes difficult, and recognizable isoelectric segments may be absent. The pattern lies within the spectrum of organized ventricular tachyarrhythmias and their possible evolution toward ventricular fibrillation, without necessarily representing a distinct disease with a single cause or a single circuit.

Its clinical significance is generally serious: the very high rate markedly reduces filling and may abolish effective cardiac output. Presentation may consist of sudden syncope or cardiac arrest, while a brief phase with residual circulation does not exclude rapid deterioration. Assessment of pulse and perfusion takes priority over choosing a label among flutter, very rapid ventricular tachycardia, and fibrillation. In the absence of circulation, all of these shockable ventricular configurations require immediate intervention.

The description of flutter remains useful when it helps reconstruct arrhythmia organization and the sequence preceding cardiac arrest. Ventricular fibrillation shows greater disorganization, whereas monomorphic ventricular tachycardia may retain distinguishable complexes. Boundaries are not always sharp in brief recordings and must not become a reason to delay treatment. This monograph focuses primarily on the value of the pattern, its differential diagnoses, and its relationship with the underlying substrate.

Electrical organization and hemodynamic consequences

Ventricular flutter shows an activation sequence that remains relatively organized, but with cycles so short that depolarization and repolarization merge. A sinusoidal surface pattern does not demonstrate that all myocardium activates simultaneously or that a single circular pathway is present. The ECG represents the sum of electrical forces and may conceal complex spatial organization. The term therefore describes an observable behavior, whereas the mechanism requires information about the context and onset of the episode.

Very rapid reentry may produce this pattern, particularly when conduction and refractoriness allow short cycle lengths. Initially monomorphic activity may accelerate and lose separation between complexes or transition to less stable propagation. In vulnerable myocardium, wavefront fragmentation may transform organized activity into fibrillation. This evolution is possible but not obligatory: not every cardiac arrest passes through a recognizable flutter phase, and not every sinusoidal segment reveals its full history.

Substrate heterogeneity influences stability. Scar, ischemia, abnormalities of ionic currents, and regional differences in recovery may promote functional block and modify the impulse pathway. A premature beat may act as a trigger, whereas maintenance depends on broader tissue properties. The morphology of the first beat and that of the final phase therefore answer different questions: the former may point toward a trigger, while the latter describes the degree of organization reached by the arrhythmia.

The reduction in cardiac output results from shortened diastole, loss of atrioventricular coordination, and inefficient contraction. In the presence of heart disease or ischemia, reserve is further reduced. Hemodynamic compromise may occur so rapidly that the monitor still shows apparently regular electrical activity while the circulation is already ineffective. An orderly electrical wave does not equate to useful systole and should not be interpreted as a reason to postpone clinical assessment for cardiac arrest.

Ischemia secondary to the arrhythmia may aggravate the initiating mechanism. Reduced coronary perfusion and increased energy demand progressively alter excitability and conduction, facilitating further instability. The relationship between arrhythmia and ischemia may therefore become circular: ischemia initiates the event and the event worsens ischemia. Restoring rhythm is essential but does not automatically eliminate persistent coronary disease or the consequences of the hypoperfusion period.

Defibrillation aims to interrupt the wavefronts sustaining the arrhythmia by applying an adequate electrical field. It does not guarantee that the subsequent rhythm will be sinus rhythm or that circulation will immediately resume. After an effective shock, bradycardia, pulseless electrical activity, or recurrence of the same tachyarrhythmia may occur. Assessment must therefore continue according to the resuscitation pathway, avoiding confusion between disappearance of the pattern and hemodynamic recovery.

Causes and clinical settings

Ischemic heart disease is an important setting, both during acute ischemia and on a scar-related substrate. A very rapid tachycardia may occur near the time of coronary occlusion, during ischemic instability, or as the evolution of a circuit in a healed infarct. The sinusoidal appearance alone cannot distinguish these scenarios. Preceding symptoms, ECGs before and after the event, ventricular function, and coronary assessment contribute to determining which component requires cause-specific treatment.

Cardiomyopathies may provide a substrate of fibrosis, conduction heterogeneity, and electrical vulnerability. In dilated, arrhythmogenic, hypertrophic, or inflammatory forms, risk is not fully represented by ejection fraction. Relatively preserved function does not exclude scar relevant to the arrhythmia. When possible, flutter observed during the event should be interpreted in the context of the specific disease because prevention and family assessment differ among etiologies.

Drugs and substances may cause proarrhythmia by altering conduction or repolarization. Intraventricular slowing due to sodium-channel blockade may produce very wide complexes and rhythms that are difficult to classify, whereas QT prolongation may favor polymorphic arrhythmias. Not every near-sinusoidal signal in a patient taking antiarrhythmic drugs has the same mechanism. Medication review includes dose, interactions, renal and hepatic function, and possible nonprescribed exposures.

Inherited electrical diseases should be considered when cardiac arrest occurs without evident heart disease or under suggestive circumstances or family history. Brugada syndrome, long-QT syndromes, and catecholaminergic arrhythmias have different mechanisms and treatments even when the terminal phase appears similar. An ECG recorded only during collapse cannot establish the subtype. The baseline tracing and triggering circumstances should be retrieved, taking into account the effects of resuscitation on subsequent findings.

Abnormalities of potassium, magnesium, oxygenation, and acid-base balance may facilitate instability or modify the tracing. In critically ill patients they often coexist with ischemia, dysfunction, and drug effects. Severe potassium abnormalities may also produce a sinusoidal appearance requiring a specific differential diagnosis. Correcting an abnormal value does not prove that it was the sole cause of the event, but it is an essential part of treatment when a causal relationship is plausible.

In a patient with an implantable cardioverter-defibrillator, documentation may come from stored electrograms and therapies. A zone labeled fibrillation often identifies a programmed rate interval and does not certify the exact morphology of the arrhythmia. Very rapid organized episodes may be classified by the device in the same zone as disorganized fibrillation. Signal review is therefore necessary to reconstruct the rhythm, distinguish recurrences, and assess the appropriateness of device interventions.

ECG appearance and major interpretation pitfalls

The characteristic finding is rapid, near-sinusoidal activity, with broad complexes following one another without clear separation between depolarization and repolarization. Axis and amplitude may remain relatively constant over part of the recording. A high rate supports the description, but there is no numerical threshold that universally separates flutter from ventricular tachycardia. Filters, the recorded lead, and segment duration may modify the impression of regularity.

The distinction from ventricular fibrillation concerns the degree of organization, but coarse fibrillation may appear relatively regular for a few cycles. Multiple leads and a longer recording help identify variability, provided they do not delay treatment. In a pulseless patient, the distinction does not change the need for rapid defibrillation. Detailed analysis becomes most valuable after stabilization, when the mechanism is reconstructed.

A very rapid monomorphic ventricular tachycardia may retain recognizable QRS complexes or progressively evolve into a tracing with confluent complexes. Along this continuum, the term flutter may describe the faster phase rather than demonstrate a new arrhythmia. Comparison with the beginning of the episode may reveal a monomorphic circuit or a repetitive trigger. Assigning separate prognostic meanings based on the label alone risks obscuring the actual history of the event.

Atrial flutter with one-to-one conduction, particularly in the presence of drugs that slow intraventricular conduction, may produce a very rapid wide-complex tachycardia. In that situation the term flutter refers to the atria, not the ventricles. Atrial activity, the atrioventricular relationship, and previous tracings help establish the diagnosis but may be difficult to recognize during instability. Pre-excited tachycardia also requires consideration. Uncertainty should be managed in a way that protects the patient from the risks of inappropriate therapy.

In severe hyperkalemia, QRS complexes and T waves may merge into a sinusoidal wave; the rate and ECG progression may differ from a rapid ventricular tachycardia. The setting of renal failure, medications, or metabolic abnormalities is informative but does not replace urgent verification. When circulation is absent, resuscitation is performed and the suspected cause is treated according to the specific pathway. The pattern must not lead clinicians to overlook a correctable condition requiring interventions beyond antiarrhythmic drugs alone.

Artifact may mimic a ventricular tachyarrhythmia, particularly during movement, chest compressions, or poor electrode contact. Persistence of normal complexes through the disturbance, discordance between channels, and assessment of perfusion help recognize it. A conscious person with a regular pulse and an apparently chaotic monitor requires immediate signal verification. In an unconscious patient without circulation, however, seeking a perfect recording must not delay resuscitative action.

Treatment of the episode and recognition of cardiac arrest

The initial decision concerns the presence of effective circulation. An unresponsive person with absent or abnormal breathing and no signs of circulation should be treated as being in cardiac arrest according to the context and the responder's skills. Gasping is not normal ventilation. Pulse assessment by healthcare professionals must not be prolonged to the point of delaying chest compressions. The monitor is used to recognize a shockable rhythm, not to replace assessment of the patient.

In pulseless ventricular flutter, cardiopulmonary resuscitation and early defibrillation are initiated. Compressions should be high quality with minimal interruptions while the defibrillator is prepared. Energy is selected according to waveform and device instructions, with escalation when appropriate. The need for a twelve-lead ECG, vascular access, or a complete etiologic diagnosis does not precede the first shock when the rhythm is already clearly shockable.

After the shock, compressions are resumed promptly, avoiding an unnecessary pause to observe the monitor for a prolonged period. Apparent electrical organization does not demonstrate return of circulation. Rhythm and perfusion are reassessed according to the algorithm while ventilation, vascular access, and the search for causes are coordinated without interfering with fundamental measures. Team organization is part of treatment because tasks performed sequentially rather than in a coordinated manner may increase no-flow time.

If a pulse is present but there are signs of instability, electrical treatment remains the priority. When the rhythm is organized and the defibrillator can reliably identify the complexes, synchronized cardioversion may be used according to the clinical picture. In sinusoidal activity in which synchronization is unreliable, or during rapid degeneration, waiting through repeated synchronization attempts may be dangerous and an unsynchronized shock may be necessary. The choice is guided by the actual rhythm and urgency, not solely by the name assigned to the tracing.

Drugs used in shockable cardiac arrest are administered according to the sequence specified by guidelines without replacing shocks and compressions. After stabilization, antiarrhythmic selection depends on the mechanism: ischemic arrhythmia, torsades de pointes, and catecholaminergic disease do not require the same strategy. Unplanned accumulation of drugs may worsen hypotension, conduction, and repolarization. Interpretation of the QT interval and the sequence preceding the event is particularly important when trying to prevent another arrhythmia.

Immediate recurrences require a search for an ongoing factor such as ischemia, electrolyte abnormalities, or intense sympathetic stimulation. Transient rhythm restoration does not end the emergency if the patient repeatedly returns to tachyarrhythmia. When episodes meet the pattern of electrical storm, treatment of the substrate, adrenergic control, device management, and electrophysiological assessment are required. Circulatory support and other advanced strategies are reserved for selected cases and centers able to provide them.

Etiologic investigation after stabilization and secondary prevention

The tracing before the event and the first seconds of the tachyarrhythmia may reveal information that the sinusoidal phase no longer preserves. A reproducible premature ventricular contraction, prolonged QT, a pause-dependent sequence, or an initially monomorphic tachycardia point toward different mechanisms. Data are collected from monitors, external defibrillators, implanted devices, and previous recordings. Preserving them prevents all decisions from being based on a single terminal segment lasting only a few seconds.

The subsequent ECG, electrolytes, renal function, and medication review constitute an initial assessment. Repolarization abnormalities after cardiac arrest, shocks, medications, or changes in temperature may be transient and may not represent the baseline phenotype. Troponin may rise for reasons other than an acute coronary occlusion. Suspected ischemia is therefore evaluated using the overall data rather than a single marker as definitive proof of mechanism.

Urgent coronary assessment is essential when there are signs of ST-elevation myocardial infarction or instability compatible with ongoing ischemia. In stable survivors without these features, timing and modality are selected according to clinical probability. Echocardiography defines function and regional abnormalities; cardiac magnetic resonance may identify scar, inflammation, or cardiomyopathy. Dysfunction immediately after cardiac arrest may include a reversible component and requires appropriate reassessment.

When no evident cause emerges, the workup includes investigation for inherited electrical diseases and early substrates, with selected testing and specialist counseling. Drug-provocation tests, exercise testing, and genetics are used according to phenotype rather than as an identical mandatory list for every patient. A variant of uncertain significance does not establish a cause, and a normal initial evaluation does not exclude the possibility that later information will clarify the case. A diagnosis of idiopathic arrhythmia requires a sufficiently complete investigation and coherent surveillance.

An implantable cardioverter-defibrillator may be indicated for secondary prevention when the event is not attributable to a completely reversible cause and the expected benefit is appropriate to the overall clinical picture. The word flutter does not by itself determine the indication: cardiac arrest, underlying disease, reversibility, and residual risk matter. Correction of an electrolyte abnormality does not automatically demonstrate that all risk has disappeared if a structural substrate remains. The decision should explicitly identify which components have been corrected and which persist.

Ablation may be useful when ventricular flutter represents the evolution of an identifiable monomorphic tachycardia or when a repetitive trigger initiates episodes. In other cases there may be no single circumscribed target. Drug therapy and treatment of the underlying heart disease may reduce recurrences, while the device provides protection from events that nevertheless occur. The strategy is built around the demonstrated mechanism rather than the assumption that every sinusoidal form corresponds to the same circuit.

Prognosis, follow-up, and significance of documentation

Immediate prognosis depends primarily on time to resuscitation and defibrillation, quality of support, and the cause of the event. The apparent regularity of the tracing cannot by itself estimate the duration of cardiac arrest or the probability of neurologic recovery. After restoration of circulation, management includes perfusion, oxygenation, temperature control, and prevention of further injury according to the post-cardiac arrest pathway. Outcome cannot be reduced to successful electrical conversion.

Long-term prognosis is determined by heart disease and reversibility. An event during a correctable acute phase is not interpreted in the same way as a tachyarrhythmia arising on persistent scar, but the distinction requires adequate evidence. Function, imaging, recurrence, and etiologic diagnosis are reassessed over time. Recovery of ejection fraction may be favorable without automatically negating a previous secondary-prevention indication based on other factors.

In patients with implanted devices, follow-up analyzes electrograms, therapies, and programming. A high rate may place an organized tachycardia in a programmed fibrillation zone, whereas rate-slowing drugs may change detection. The goal is to ensure protection while reducing unnecessary therapies, without delaying treatment of poorly tolerated arrhythmias. Review should be specific to the documented arrhythmias and not based solely on the total number of shocks.

Therapy surveillance includes conduction, QT interval, organ function, and interactions according to the drugs used. A regimen that is well tolerated may become hazardous during an intercurrent illness or after new prescriptions. Recurrences also require investigation for progression of the substrate or a new acute cause. Not every subsequent episode repeats the initial mechanism, and a different morphology may require an updated strategy.

Survivors may experience neurologic consequences, fear of recurrence, and limitations in daily life. Rehabilitation, psychological support, and clear information about the care plan are components of treatment. Physical activity, work, and driving are evaluated according to the diagnosis, arrhythmia control, and applicable regulations. The presence of a device does not eliminate the emotional impact of the event or make a recovery pathway unnecessary.

The report should distinguish the observed pattern from the causal diagnosis: duration, regularity, transition from or to other rhythms, presence of a pulse, and treatments received should be documented. The term ventricular flutter alone does not provide a prognostic model independent of other malignant tachyarrhythmias. Its usefulness lies in accurately describing a phase of the event and linking it to the substrate. Complete documentation allows this information to be used without turning an electrocardiographic category into a sufficient explanation of the disease.